Intestinal fatty acid binding protein polymorphism at codon 54 is not associated with postprandial responses to fat and glucose tolerance tests in healthy young Europeans. Results from EARS II participants.
Polymorphism Ala54Thr of the intestinal fatty acid-binding protein 2 (FABP2) has been reported to have an effect on the protein's affinity for long chain fatty acids and to be associated with serum lipid and insulin levels in fasting and especially postprandial states. We wanted to test whether this genetic variation is associated with fasting and postprandial glucose, insulin or lipid levels in 666 male university students participating in the second European Atherosclerosis Study (EARS II). We also studied whether the subgroup of 330 students with paternal history of myocardial infarction (MI) before the age of 55 have different genotype distribution than 336 matched controls.


RESULTS
No difference in genotype distribution was observed between offspring with and without paternal history of MI or between populations from 11 European countries. The frequency of the threonine encoding allele was 0.276 in cases and 0.266 in controls. There were no differences in fasting or postprandial serum lipid, glucose or insulin levels between subjects having different genotypes.


CONCLUSIONS
In this study FABP2 Ala54Thr polymorphism was not associated with lipid or glucose metabolism. In addition to environmental and genetic factors, selection of study population also may explain the difference between this and earlier studies.
Tahvanainen
E
E
Department of Biochemistry, National Public Health Institute, Mannerheimintie 166, 00300, Helsinki, Finland. esa_tahvanainen@merck.com
Molin
M
M
Vainio
S
S
Tiret
L
L
Nicaud
V
V
Farinaro
E
E
Masana
L
L
Ehnholm
C
C
D000293:Adolescent; D000328:Adult; D001161:Arteriosclerosis / Q000235:genetics / Q000378:metabolism; D001786:Blood Glucose / Q000032:analysis; D002352:Carrier Proteins / Q000235:genetics* / Q000378:metabolism; D003062:Codon; D004041:Dietary Fats / Q000008:administration & dosage*; D005215:Fasting; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D005227:Fatty Acids / Q000235:genetics* / Q000378:metabolism; D005838:Genotype; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D007413:Intestinal Mucosa / Q000378:metabolism*; D008055:Lipids / Q000097:blood; D008297:Male; D009203:Myocardial Infarction / Q000235:genetics / Q000378:metabolism; D009363:Neoplasm Proteins; D011110:Polymorphism, Genetic; D019518:Postprandial Period; D025521:Tumor Suppressor Proteins
D001786:Blood Glucose; D002352:Carrier Proteins; D003062:Codon; D004041:Dietary Fats; C493404:FABP2 protein, human; C107608:FABP7 protein, human; C493405:Fabp2 protein, mouse; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D005227:Fatty Acids; D007328:Insulin; D008055:Lipids; D009363:Neoplasm Proteins; D025521:Tumor Suppressor Proteins